We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.
- Authors
Oppenheim, D E; Spreafico, R; Etuk, A; Malone, D; Amofah, E; Peña-Murillo, C; Murray, T; McLaughlin, L; Choi, B S; Allan, S; Belousov, A; Passioukov, A; Gerdes, C; Umaña, P; Farzaneh, F; Ross, P
- Abstract
The epidermal growth factor receptor (EGFR) is overexpressed in colorectal cancer (CRC), and is correlated with poor prognosis, making it an attractive target for monoclonal antibody (mAb) therapy. A component of the therapeutic efficacy of IgG1 mAbs is their stimulation of antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells bearing the CD16 receptor. As NK cells are functionally impaired in cancer patients and may be further compromised upon chemotherapy, it is crucial to assess whether immunotherapeutic strategies aimed at further enhancing ADCC are viable.
- Publication
British journal of cancer, 2014, Vol 110, Issue 5, p1221
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2014.35